Utilization of temperature kinetics as a method to predict treatment intensity and corresponding treated wood quality : durability and mechanical properties of thermally modified wood

Wood heat treatment is an attractive alternative to improve decay resistance of wood species with low natural durability. However, this improvement of durability is realized at the expense of the mechanical resistance. Decay resistance and mechanical properties are strongly correlated to thermal degradation of wood cells wall components. Mass loss resulting from this degradation is a good indicator of treatment intensity and final treated wood properties. However, the introduction of a fast and accurate system for measuring this mass loss on an industrial scale is very difficult. Nowadays, many studies are conducted on the determination of control parameters which could be correlated with the treatment conditions and final heat treated wood quality such as decay resistance. The aim of this study is to investigate the relations between kinetics of temperature used during thermal treatment process representing heat treatment intensity, mass losses due to thermal degradation and conferred properties to heat treated wood. It might appear that relative area of treatment temperature curves is a good indicator of treatment intensity. Heat treatment with different treatment conditions (temperature-time) have been performed under vacuum, on four wood species (one hardwood and three softwoods) in order to obtain thermal degradation mass loses of 8, 10 and 12%. For each experiment, relative areas corresponding to temperature kinetics, mass loss, decay resistance and mechanical properties have been determined. Results highlight the statement that the temperature curves’ area constitutes a good indicator in the prediction of needed treatment intensity, to obtain required wood durability and mechanical properties such as bending resistance and Brinell hardness.LERMaB is supported by the French National Research Agency through the Laboratory of Excellence ARBRE (ANR-12- LABXARBRE-01), the authors gratefully acknowledge this ai

Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping review

Objective: The purpose of this study was to map and describe the studies that have investigated therapeutic alternatives for the management of paediatric multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Considering the origin of the studies performed (low-, middle- and high-income countries), a systematic scoping review was conducted with primary studies that reported the use of medications for the treatment of patients with MIS-C.Sources: The searches were performed in MEDLINE, Embase, Lilacs, Epistemonikos, CINAHL, and CENTRAL, in the grey literature (theses and dissertations from CAPES, ProQuest, and PROSPERO) and in clinical trial databases until May 2022. The selection and extraction of studies were performed independently by two reviewers.Summary of the findings: A total of 173 studies were included, most of which were published as case reports or series. No randomized controlled clinical trials (RCTs) were identified. The investigated drugs were immunoglobulins, glucocorticoids, monoclonal antibodies, anticoagulants, and antiplatelet agents.Conclusion: The dosages, when reported, were heterogeneous among the studies. The ethnicity and comorbidity of the participants were poorly reported. Monoclonal antibodies, drugs with higher costs, were mostly described in studies of high-income countries

Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

International audienceRationale: Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. Objectives: To evaluate the effects of elexacaftor-tezacaftor- ivacaftor in patients with CF and advanced respiratory disease. Methods: A prospective observational study, including all patients aged ⩾12 years and with a percent-predicted FEV1 (ppFEV1) <40 who initiated elexacaftor-tezacaftor-ivacaftor from December 2019 to August 2020 in France was conducted. Clinical characteristics were collected at initiation and at 1 and 3 months. Safety and effectiveness were evaluated by September 2020. National-level transplantation and mortality figures for 2020 were obtained from the French CF and transplant centers and registries. Measurements and Main Results: Elexacaftor-tezacaftor- ivacaftor was initiated in 245 patients with a median (interquartile range) ppFEV1 = 29 (24-34). The mean (95% confidence interval) absolute increase in the ppFEV1 was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventilation, and/or enteral tube feeding decreased by 50%, 30%, and 50%, respectively (P < 0.01). Although 16 patients were on the transplant waiting list and 37 were undergoing transplantation evaluation at treatment initiation, only 2 received a transplant, and 1 died. By September 2020, only five patients were still on the transplantation path. Compared with the previous 2 years, a twofold decrease in the number of lung transplantations in patients with CF was observed in 2020, whereas the number of deaths without transplantation remained stable. Conclusions: In patients with advanced disease, elexacaftor-tezacaftor-ivacaftor is associated with rapid clinical improvement, often leading to the indication for lung transplantation being suspended